Recent Updates
Recently added Catalysts
RARE Negative Sentiment Score: 25/100

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

Key Takeaway: Ultragenyx Pharmaceutical Inc. is under scrutiny due to a class action lawsuit against it for allegedly failing to disclose crucial information. Investors who purchased shares between August 3, 2023, and December 26, 2025, have until April 6, 2026, to file lead plaintiff applications. The lawsuit follows disappointing results from the Phase 3 studies of setrusumab for Osteogenesis Imperfecta, which failed to demonstrate significant efficacy. This triggered a sharp decline in the company's stock price, highlighting the depth of investor concerns surrounding Ultragenyx's communications and performance.

Market Sentiment Analysis

CONCERNS & RISKS

  • Ultragenyx is facing a class action lawsuit for failing to disclose material information.
  • The company's Phase III studies for setrusumab failed to show significant effectiveness.
  • Following the announcement of the failed studies, Ultragenyx's stock price dropped by approximately 42%.

Full Press Release Details

NEW ORLEANS, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE), if they purchased or otherwise acquired the Company’s shares between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Ultragenyx investors should visit us at https://claimsfiler.com/cases/nasdaq-rare/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Ultragenyx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 26, 2025, the Company announced the “results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta” disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company “is evaluating its planned operations and will promptly define and implement significant expense reductions.” On this news, the price of Ultragenyx’s shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.
The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline for filing a lead plaintiff application?

Investors must file lead plaintiff applications by April 6, 2026.

What is the class period for the Ultragenyx lawsuit?

The class period spans from August 3, 2023, to December 26, 2025.

What caused the drop in Ultragenyx's stock price?

The stock fell due to the failure of clinical trials for setrusumab.

How can investors learn more about their legal options?

Investors can visit ClaimsFiler or call toll-free at 844-367-9658.

What lawsuit is mentioned in the article?

The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., No. 26-cv-01097.

Last updated: Feb 19, 2026